Latest news
IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib - Pharmaceutical TechnologyPharmaceutical Technology · Mon, 03 Aug 2026 11:22:18 GMTIMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.commarketscreener.com · Fri, 31 Jul 2026 10:50:46 GMTIMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand - The Manila TimesThe Manila Times · Fri, 31 Jul 2026 08:06:11 GMTIMPACT Therapeutics Strikes EUR423.5 Million Global Senaparib Deal With Pharmanovia - TipRanksTipRanks · Thu, 30 Jul 2026 10:50:04 GMT